Preparation, Pharmacokinetics, and Antitumor Potential of Miltefosine-Loaded Nanostructured Lipid Carriers

Abstract

Background The purpose of this study was to investigate the suitability of nanostructured lipid carriers (NLCs) loaded with miltefosine (HePC) as an anticancer drug for the treatment of breast cancer. Methods HePC-NLCs were prepared using a microemulsion technique and then evaluated for particle size, polydispersity index (PDI), incorporation efficiency, in vitro release of entrapped drug, and hemolytic potential. Furthermore, pharmacokinetic, biodistribution, and liver toxicity analyses were performed in Sprague–Dawley rats, and antitumor efficacy was evaluated in Michigan Cancer Foundation-7 (MCF-7) and squamous cell carcinoma-7 (SCC-7) cells in vitro and in tumour-bearing BALB/c mice in vivo. Advanced analyses including survival rate, immunohistopathology, and terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assays were performed to evaluate apoptosis in vivo. Results The average particle size of the HePC-NLCs was 143 ± 16 nm, with a narrow PDI (0.104 ± 0.002), and the incorporation efficiency was found to be 91 ± 7%. The NLCs released HePC in a sustained manner, and this release was significantly lower than that of free drug. The in vitro hemolytic assay demonstrated a significantly reduced hemolytic potential (~9%) of the NLCs compared to that of the test formulations. The HePC-NLCs demonstrated enhanced pharmacokinetic behaviour over free drug, including extended blood circulation and an abridged clearance rate in rats. Furthermore, the HePC-NLCs exhibited higher cytotoxicity than the free drug in MCF-7 and SCC-7 cells. Moreover, the HePC-NLCs showed significantly enhanced ( P < 0.005) antitumor activity compared to that of the control and free drug-treated mouse groups. Tumour cell apoptosis was also confirmed, indicating the antitumor potential of the HePC-NLCs. Conclusion These findings demonstrate the ability of NLCs as a drug delivery system for enhanced pharmacokinetic, antitumor, and apoptotic effects, most importantly when loaded with HePC.

Polycaprolactone based pharmaceutical nanoemulsion loaded with acriflavine: optimization andin vivoburn wound healing activity

“…The initial burst release was due to some acriflavine presence on the surface of ACR-PCL-NE globules or dispersed in PVA which also have drug entrapment capabilities. The idea that the drug is ensnared within a nanoemulsion droplet cannot be ignored once there is a gradual release over time, since the cumulative release reached an almost steady state at the end of the experiment (Yu et al., 2021a ; Kim et al., 2021 ).…”

Miltefosine Against Scedosporium and Lomentospora Species: Antifungal Activity and Its Effects on Fungal Cells

“…Haemolytic activity was observed only at a miltefosine concentration of about 35-40 µg/ml (Widmer et al, 2006;Obando et al, 2007;Valenzuela-Oses et al, 2017), which is almost 10 fold higher than the MIC found for Scedosporium and Lomentospora planktonic cells in our work. In addition, the cytotoxicity of miltefosine has already been evaluated in a variety of cell lineages, and toxic concentrations were found to be around 38 and 51 µg/ml in MFC (mouse forestomach carcinoma) and SSC (spermatogonial stem cell) cells, respectively (Yu et al, 2021), 21.75 µg/ml in H358 cells (Valenzuela-Oses et al, 2017) and > 25 µg/ml in Vero and HepG2 cells (Ravu et al, 2013). Alginate-nanoencapsulated miltefosine has already been formulated in previous studies and presented no haemolytic or toxic effect in Galleria mellonella (Spadari et al, 2019), and the cytotoxic concentrations of micelle-encapsuled miltefosine were found to be 2-3 times higher than the free drug (Valenzuela-Oses et al, 2017).…”

Development, Characterization, and Evaluation of SLN-Loaded Thermoresponsive Hydrogel System of Topotecan as Biological Macromolecule for Colorectal Delivery

“…TPT-SLNs were prepared by microemulsion technique with a little modification [ 27 , 28 ]. A mixture of Span 20 and tricaprin was added to Tween 80 at elevated temperature, followed by addition of 1 mL distilled water under continuous stirring, until a transparent microemulsion was formed.…”